- Poster presentation
- Open Access
Levosimendan: experience of an adult ICU
© BioMed Central Ltd 2006
- Published: 21 March 2006
- Myocardial Infarction
- Atrial Fibrillation
- Acute Myocardial Infarction
- Cardiac Index
The prognosis of patients admitted to the ICU with cardiogenic shock is poor.
Data were collected retrospectively between January 2004 and June 2005. Cardiac studies and inotrope use were evaluated using Wilcoxon matched-pairs testing.
Twenty-eight patients received levosimendan. Ten (34%) patients were admitted following cardiac surgery and nine (31%) post acute myocardial infarction. The mean APACHE II score at time of levosimendan was 19 (SE = 0.96). No patients received a loading dose. The median maintenance dose was 0.1 μg/kg/min for a median of 24 hours (range = 3–58). A reduction in the mean dose of dobutamine (8.26 vs 3.77 μg/kg/min, n = 7, P = 0.031) and milrinone (0.22 vs 0.12 μg/kg/min, n = 8, P = 0.031) was seen 24 hours post levosimendan. A single patient developed atrial fibrillation and there were no new reports of ischaemia. ICU mortality was 62%.
Key outcome measures
Reason for admission to the ICU
APACHE II score at initiation of levosimendan
Levosimendan dose and duration
Concurrent inotrope use